BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
by Zacks Equity Research
CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
Vanda (VNDA) Q4 Earnings: What's in Store for the Stock
by Zacks Equity Research
On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
by Zacks Equity Research
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
BioDelivery Sciences International (BDSI) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include: Rent-A-Center, BioDelivery , Seabridge, Marchex and DSP
by Zacks Equity Research
Zacks.com featured highlights include: Rent-A-Center, BioDelivery , Seabridge, Marchex and DSP
5 Breakout Stocks Offering Impressive Returns
by Swarup Gupta
The logic behind this kind of stock selection is to determine which stocks are trading within a narrow band.
BioDelivery (BDSI) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.
BioDelivery Sciences International (BDSI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 28.57% and -0.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
BioDelivery Sciences International (BDSI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
BioDelivery (BDSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can The Uptrend Continue for BioDelivery Sciences International (BDSI)?
by Zacks Equity Research
Investors certainly have to be happy with BioDelivery Sciences International, Inc. (BDSI) and its short term performance.
BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.
BioDelivery Sciences International (BDSI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 15.79% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More
by Zacks Equity Research
Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.
Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?
by Zacks Equity Research
Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.
Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).